EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Burden of female‐specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021

Wenhui Ren, Xiangyu Guo, Zheng Liu, Yanqiu Wu, Rui Peng, Huixin Liu iD, Jinlei Qi

Cancer · 15.01.2025 · 131 (2)

DOI: 10.1002/cncr.35712 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 07.01.2025. Verfasst von Wenhui Ren und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology and Biostatistics, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Global Burden of Disease, Breast Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Capital's Funds for Health Improvement and Research, National Natural Science Foundation of China, Public Health Advanced Training Programme of Ministry of Education of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast cancer and reproductive system cancers remain significant public health threats for Chinese women. This study aimed to evaluate the latest epidemiological patterns and trends of four female‐specific cancers in China.

Methods

The year‐ and age‐specific estimates of the incidence, mortality, and disability‐adjusted life‐years (DALYs) associated with breast, cervical, ovarian, and uterine cancers in China from 1990 to 2021 were generated from the Global Burden of Disease, Injuries, and Risk Factors 2021 study. The epidemiological characteristics were analyzed with age–period–cohort models. A Bayesian age–period–cohort model was applied to forecast disease burden from 2022 to 2050.

Results

In 2021, China reported 385.84 thousand (95% uncertainty interval [UI], 294.10–489.01 thousand) incident cases of female breast cancer, followed by cervical cancer (132.79 thousand [95% UI, 95.96–172.60 thousand]), uterine cancer (72.02 thousand [95% UI, 53.31–100.00 thousand]), and ovarian cancer (41.24 thousand [95% UI, 30.30–54.55 thousand]). Breast cancer ranked as the primary cause of cancer‐related deaths, followed by cervical cancer. The age‐specific incidence rate for breast, cervical, ovarian, and uterine cancers are projected to occur in the age groups 60–64 years, 55–59 years, 65–69 years, and 60–64 years, respectively. Breast, ovarian, and uterine cancer cases are projected to rise by 2050, which will exceed those recorded in 2021.

Conclusions

Various inequities have been identified across four types of cancers affecting women, which underscores the need for tailored national cancer control strategies. Emphasis should be placed on primary prevention and screening for breast and cervical cancers, whereas efforts for uterine and ovarian cancers should focus on implementing early diagnosis and treatment measures. Plain language summary This study examines the burdens and trends of breast, cervical, ovarian, and uterine cancers among Chinese women from 1990 to 2021. In 2021, breast cancer emerged as the most prevalent, followed by cervical, uterine, and ovarian cancers, with breast cancer also exhibiting the highest mortality rate. The age groups projected to exhibit the highest incidence rates for breast, cervical, ovarian, and uterine cancers are 60–64 years, 55–59 years, 65–69 years, and 60–64 years, respectively. Projections indicate that by 2050, the incidence of breast, ovarian, and uterine cancers will surpass 2021 levels, which underscores the necessity for targeted prevention, early detection, and treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Global Burden of DiseaseBreast NeoplasmsHumansFemaleChinaMiddle AgedAgedIncidenceAdultUterine Cervical NeoplasmsUterine NeoplasmsBayes TheoremOvarian NeoplasmsDisability-Adjusted Life YearsYoung AdultAdolescentAged, 80 and overRisk Factors

Stichwörter der Autor:innen

age–period–cohort analysisbreast cancercervical cancerdisease burdenovarian cancerpredictionuterine cancer

Autor:innen und Institutionen

  • Department of Clinical Epidemiology and Biostatistics, Peking University People's Hospital, Beijing, China.
  • Department of Neuro-Oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Department of Clinical Epidemiology and Biostatistics, Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • National Center for Chronic and Non-Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

ORCID-Profile: Huixin Liu

Förderung

  • Capital's Funds for Health Improvement and Research
  • National Natural Science Foundation of China
  • Public Health Advanced Training Programme of Ministry of Education of the People's Republic of China

Zitieren

APA

Ren, W., Guo, X., Liu, Z., Wu, Y., Peng, R., Liu, H., & Qi, J. (2025). Burden of female‐specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021. Cancer, 131(2). https://doi.org/10.1002/cncr.35712

Vancouver

Ren W, Guo X, Liu Z, Wu Y, Peng R, Liu H, et al. Burden of female‐specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021. Cancer. 2025;131(2). doi:10.1002/cncr.35712

BibTeX
@article{Ren2025,
  author = {Ren, Wenhui and Guo, Xiangyu and Liu, Zheng and Wu, Yanqiu and Peng, Rui and Liu, Huixin and Qi, Jinlei},
  title = {Burden of female‐specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {2},
  doi = {10.1002/cncr.35712}
}
Kostenlos starten →